The Shingrix vaccine from GSK PLC - shingles protection with strong real-world data

The Shingrix vaccine offers high protection against shingles for adults over 50, with efficacy rates around 90 percent in large clinical trials. This bestseller drives the price of GSK PLC shares (ISIN GB0009252882).

Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-30, 14:22. Details in the imprint.

The Shingrix vaccine is the kind of product you remember when you watch a relative wince from shingles pain on a quiet Sunday afternoon. The vial looks ordinary, but for many patients the promise of avoiding burning rash and nerve pain is very real. In the consultation room, the nurse’s gloved hand feels reassuring as the suspension goes into the upper arm.

How Shingrix is built

Shingrix from GSK PLC is a recombinant, non-live vaccine designed specifically to prevent shingles, or herpes zoster, in adults. It uses a varicella zoster virus glycoprotein E antigen combined with GSK’s AS01B adjuvant system to trigger a strong immune response.GSK press release on EU approval The formulation is non-live, which matters for many older adults with weakened immunity.

The vaccine is supplied as two components that need to be mixed just before use, one as a lyophilised powder and one as a liquid adjuvant suspension.EMA product information Doctors often mention that once reconstituted, the suspension looks milky and slightly opaque. That visual cue helps them confirm they have shaken it enough and that the components are properly combined.

What the data shows

The standard Shingrix schedule is two intramuscular doses of 0.5 ml, given two to six months apart, for adults aged 50 years and older.CDC shingles vaccine guidance Some national programmes have extended recommendations to immunocompromised adults from 18 years upwards, reflecting broader risk patterns.

In pivotal clinical trials involving tens of thousands of participants, Shingrix showed around 97 percent efficacy in adults aged 50 to 69 and about 91 percent in those aged 70 and older against shingles episodes.New England Journal of Medicine trial report Those numbers are significantly higher than older live-attenuated shingles vaccines, which often saw efficacy dip more steeply with age.

How it feels in the arm

On the patient side, the experience is not entirely gentle. Many recipients report a sore upper arm that feels heavy and warm within a few hours, along with fatigue or mild fever. These reactions usually fade within two or three days and are a sign of the immune system being actively stimulated.

Dr. Thomas Breuer, long-time vaccine development leader at GSK, has often described Shingrix as a product that trades transient reactogenicity for robust protection, especially in older adults whose immune response needs a stronger nudge. His argument resonates with clinicians who see how severe shingles can be in everyday practice.

Real-world uptake and access

Since its first approvals in 2017 and 2018, Shingrix has rolled out across major markets, including the United States, Canada, parts of Europe and several Asian countries. In some health systems it is now reimbursed for adults over a certain age, which has helped uptake. In Germany, access typically runs via general practitioners and vaccination centres when reimbursed.

For GSK, Shingrix has become a major growth driver in its vaccines division, with sales running into billions of pounds annually in recent years. The company has reported strong demand and is working on scaling manufacturing to match broader immunisation programmes. That production scaling involves both antigen and adjuvant facilities, since AS01B is not a simple off-the-shelf ingredient.

Where Shingrix has limits

Shingrix does not treat active shingles or post-herpetic neuralgia, it only aims to prevent future episodes. People who have already had shingles are often advised to wait until symptoms have cleared before getting vaccinated, and those timing rules can frustrate patients who want an immediate solution.

The need for two doses is another practical consideration. Some adults manage only the first shot and then miss the follow-up, especially if they feel strong local reactions after dose one. Providers are experimenting with reminder systems and combined visits to keep completion rates high.

The GSK PLC share angle

For GSK, Shingrix sits at the centre of its narrative as a focused biopharma company anchored in vaccines and specialty medicines. The vaccine’s performance and continued geographic expansion play into how investors view the stability of the vaccines franchise. On the London Stock Exchange, GSK PLC shares (ISIN GB0009252882) trade under the ticker GSK in pounds sterling.

Key facts on Shingrix

• Product: Shingrix vaccine
• Manufacturer: GSK plc
• Category: New release and preventive vaccine
• Launch: Initial approvals around 2017-2018 in major markets
• RRP / Price: Pricing varies by market and reimbursement scheme, often covered partially or fully by insurance for eligible adults
• Availability: Widely available via physicians and vaccination centres in the US, Europe and other regions, subject to national recommendations
• Target group: Primarily adults aged 50 years and older, and certain immunocompromised adults from 18 years upwards
• Highlight / USP: High, age-resilient efficacy against shingles with a non-live recombinant design and adjuvant system

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.